Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 26 June 2017

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Toxins produced by C difficile effect disease severity

Research in this week's Lancet shows that the severity of C difficile-associated disease caused by polymerase chain reaction-ribotype 027 could result from hyperproduction of toxins A and B.

News image

fiogf49gjkf04

Toxins A and B are the primary virulence factors of Clostridium difficile.

Since 2002, an epidemic of C difficile-associated disease with increased morbidity and mortality has been present in Quebec province, Canada.

Dr Michel Warny and colleagues characterized the dominant strain of this epidemic.

The researchers determined whether the dominant strain produces higher amounts of toxins A and B than those produced by non-epidemic strains.

The research team obtained isolates from 124 patients from Centre Hospitalier Universitaire de Sherbrooke in Quebec.

Additional isolates from the USA, Canada, and the United Kingdom were included to increase the genetic diversity of the toxinotypes tested.

The epidemic strain was isolated from 72 with C difficile-associated disease
The Lancet

Isolate characterization included toxinotyping, pulsed-field gel electrophoresis, and polymerase chain reaction ribotyping.

The isolate characterization also included the detection of a binary toxin gene, and detection of deletions in a putative negative regulator for toxins A and B.

By use of an enzyme-linked immunoassay, the team measured the in-vitro production of toxins A and B by epidemic strain and non-dominant strain isolates.

The team found that the epidemic strain was characterized as toxinotype III, and North American pulsed-field gel electrophoresis type 1.

The polymerase chain reaction-ribotype 027 was also characterized by the epidemic strain.

The researchers noted that this strain carried the binary toxin gene cdtB and an 18-bp deletion in a putative negative regulator for toxins A and B.

The research team isolated this strain from 72 patients with C difficile-associated disease.

Peak median toxin A concentrations produced in vitro by polymerase chain reaction-ribotype 027 were 16 times higher than those measured in isolates.

The team observed that peak median toxin B concentrations produced in vitro by polymerase chain reaction-ribotype 027 were 23 times higher than those measured in isolates.

The isolates represented 12 different pulsed-field gel electrophoresis types, known as toxinotype 0.

Dr Warny's team concludes, “The severity of C difficile-associated disease caused by polymerase chain reaction-ribotype 027 could result from hyperproduction of toxins A and B.”

“Dissemination of this strain in North America and Europe could lead to important changes in the epidemiology of C difficile-associated disease.”

Lancet 2005: 366(9491):1079-84
27 September 2005

Go to top of page Email this page Email this page to a colleague

 26 June 2017 
Weight loss for low-income postpartum women
 26 June 2017 
Iron and IBD risk
 26 June 2017 
Anger in HIV-HCV co-infected patients
 23 June 2017 
Predictive model for clinical course of Crohn's disease
 23 June 2017 
Treatment for KRAS wild-type advanced colorectal cancer
 23 June 2017 
Epidemiology of Hep E
 22 June 2017 
Vonoprazan-based triple therapy on H. pylori eradication
 22 June 2017 
Adolescent transition in IBD
 22 June 2017 
Patient understanding of biologic therapy in IBD
 21 June 2017 
Hydrolyzed wheat flour improves immunogenicity in celiac disease
 21 June 2017 
Statins in chronic Hep C
 21 June 2017 
Racial disparities in colorectal cancer
 20 June 2017 
Therapies in chronic pancreatitis
 20 June 2017 
Genetic analyses for malignancy detection in biliary strictures
 20 June 2017 
Viral-associated esophagus cancers
 19 June 2017 
Global prevalence of IBS in adults
 19 June 2017 
Clinical improvement in mild acute pancreatitis
 19 June 2017 
Repeat biopsy and celiac disease outcomes 
 16 June 2017 
Exercise-induced GI syndrome—implications for intestinal disease
 16 June 2017 
HCV among reproductive-aged women and children in the USA
 16 June 2017 
Adverse events after outpatient colonoscopy
 15 June 2017 
Pioglitazone for NASH
 15 June 2017 
Urinary adverse events after rectal cancer treatment
 15 June 2017 
Treatment of eosinophilic esophagitis
 14 June 2017 
Genetics of familial colorectal cancer
 14 June 2017 
Abdominal ultrasound in blunt torso trauma
 14 June 2017 
Acute kidney injury in Hep C and sofosbuvir-based regimens
 13 June 2017 
Serrated polyps in the colon and rectum
 13 June 2017 
Colorectal cancer during pregnancy
 13 June 2017 
Biomarker for penetrating Crohn's
 12 June 2017 
Course of primary sclerosing cholangitis
 12 June 2017 
Quality of life in end-stage liver disease
 12 June 2017 
Clinical remission in patients with Crohn's disease
 09 June 2017 
Socioeconomic influences on H. pylori gastritis
 09 June 2017 
Celiac disease in Ireland
 09 June 2017 
Consultants do not follow up on GI tests they recommend
 08 June 2017 
Genetics and the gut microbiota and metabolic syndrome
 08 June 2017 
Antireflux surgery in extraesophageal reflux
 08 June 2017 
Breath testing in gastrointestinal disorders
 07 June 2017 
Multidisciplinary care and liver cancer
 07 June 2017 
Model for excluding NAFLD
 07 June 2017 
Hospital readmission in IBD
 06 June 2017 
Dietary patterns and colorectal cancer risk
 06 June 2017 
Direct-acting antiviral agents for HCV
 06 June 2017 
Medical therapies for stricturing Crohn’s
 05 June 2017 
Celiac disease prevalence in the USA
 05 June 2017 
Hospital-acquired conditions in Crohn’s disease
 05 June 2017 
Depression and IBD
 02 June 2017 
Menopausal hormone therapy and fecal incontinence
 02 June 2017 
Narcotic and corticosteroid prescriptions in IBD
 02 June 2017 
Treating anemia after gastrectomy
 01 June 2017 
Infliximab and cancer in pediatric IBD
 01 June 2017 
Health insurance policies in IBD
 01 June 2017 
Endoscopic quality improvement program for polyp detection
 31 May 2017 
Probiotics and Clostridium difficile infection
 31 May 2017 
Post-procedural adverse events after colonoscopy
 31 May 2017 
Clinical decision-making in severe alcoholic hepatitis
 30 May 2017 
Waist belts and reflux
 30 May 2017 
Colorectal cancer increases in developed and developing regions
 30 May 2017 
Antidepressants and bleeding in peptic ulcers

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us